Haemonetics Corporation (NYSE:HAE) hit a new 52-week high Wednesday as it changed hands at $64.84 compared with its previous 52-week high of $64.83. Haemonetics is currently trading at $64.77 with 33,792 shares changing hands as of 2:47 p.m.
NEW YORK ( TheStreet) -- Haemonetics Corporation (NYSE: HAE) hit a new 52-week high Wednesday as it traded at $64.84 compared with its previous 52-Week high of $64.83. Haemonetics is changing hands at $64.77 with 33,792 shares traded as of 2:47 p.m. ET. Average volume has been 164,200 shares over the past 30 days. Haemonetics has a market cap of $1.6 billion and is part of the health care sector and health services industry. Shares are up 1.6% year to date as of the close of trading on Tuesday. Haemonetics Corporation, a healthcare company, provides blood management solutions to plasma and blood collectors, blood banks, hospitals and hospital service providers, and health organizations in the United States and internationally. The company has a P/E ratio of 25.4, equal to the average health services industry P/E ratio and above the S&P 500 P/E ratio of 16.1.
Practice your HAE trading strategies and win cash in our stock game.
TheStreet Ratings rates Haemonetics as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. You can view the full Haemonetics Ratings Report. See all 52-week high stocks or get investment ideas from our investment research center.